搜索临床试验以:IPI-145 (duvelisib)
总计6050个结果
-
Fusion Pharmaceuticals Inc.终止乳腺癌 | 胃癌 | 大肠癌 | 卵巢癌 | 肺癌 | 晚期实体瘤 | 头颈部鳞状细胞癌 | 肝癌 | 膀胱癌 | 易感 FGFR3 基因改变 | FGFR3 | FGFR3 过表达 | FGFR3受体 | FGFR3 蛋白过表达美国, 澳大利亚
-
Shandong Luoxin Pharmaceutical Group Stock Co.,...完全的
-
University of PennsylvaniaNational Institutes of Health (NIH)招聘中
-
Constellation PharmaceuticalsThe Leukemia and Lymphoma Society完全的
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Massachusetts General Hospital; City of Hope Medical Center; George...主动,不招人
-
ImmuPharma完全的
-
ESSA Pharmaceuticals终止
-
Yale UniversityEdison Pharmaceuticals Inc; Rembrandt Foundation完全的
-
Serum Institute of India Pvt. Ltd.招聘中
-
Karolinska University HospitalIstituto Ortopedico Rizzoli; Sahlgrenska University Hospital, Sweden; University Hospital, Akershus 和其他合作者招聘中
-
Combangio, IncKala Pharmaceuticals, Inc.招聘中
-
Fusion Pharmaceuticals Inc.招聘中胃癌 | 大肠癌 | 尤文肉瘤 | 头颈部鳞状细胞癌 | 胰腺导管腺癌 (PDAC) | 表达实体瘤的 NTSR1 | 神经内分泌分化 (NED) 前列腺癌美国, 澳大利亚
-
Brown UniversityNational Institute of Mental Health (NIMH)完全的
-
University of VirginiaBill and Melinda Gates Foundation; International Centre for Diarrhoeal Disease Research, Bangladesh未知